Demopulos Gregory A MD 4
4 · OMEROS CORP · Filed Jun 17, 2021
Insider Transaction Report
Form 4
OMEROS CORPOMER
Demopulos Gregory A MD
DirectorChairman, CEO & President
Transactions
- Sale
Common Stock
2021-06-17$14.90/sh−36,857$549,169→ 2,026,986 total - Exercise/Conversion
Stock Option (right to buy)
2021-06-15−36,856→ 36,857 totalExercise: $4.10Exp: 2022-01-07→ Common Stock (36,856 underlying) - Exercise/Conversion
Common Stock
2021-06-15$4.10/sh+36,856$151,110→ 2,063,842 total - Exercise/Conversion
Common Stock
2021-06-17$4.10/sh+36,857$151,114→ 2,063,843 total - Exercise/Conversion
Stock Option (right to buy)
2021-06-17−36,857→ 0 totalExercise: $4.10Exp: 2022-01-07→ Common Stock (36,857 underlying) - Sale
Common Stock
2021-06-15$15.02/sh−36,856$553,577→ 2,026,986 total
Footnotes (4)
- [F1]Open market sale pursuant to a previously established Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2020 for expiring options. The trading schedule, including sale dates and the number of shares to be sold, was established at the time of the trading plan's adoption in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]This transaction was executed in multiple trades at prices ranging from $14.83 to $15.45; the price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- [F3]This transaction was executed in multiple trades at prices ranging from $14.72 to $15.06; the price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- [F4]The shares subject to this option vested and became exercisable over 48 monthly installments, with a vesting commencement date of April 1, 2011.